Payment overview · 2025
General Payments
$351.61
16 reported records · 7 companies
Healthcare provider profile · identity verified
Amarjit Singh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTH RICHMOND HILL, NY · NPI 1801951280
Verified facts
What the public records show
CMS Open Payments records show Amarjit Singh, M.D. received $351.61 in general payments during 2025 across 16 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $114.60 | 32.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $87.53 | 24.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.34 | 15.2% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $29.23 | 8.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.92 | 7.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.85 | 6.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.14 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $351.61 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $114.60 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $87.53 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $53.34 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 616 | 165 |
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 154 |
| Metformin Hcl | Metformin Hcl | 379 | 106 |
| Losartan Potassium | Losartan Potassium | 370 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 335 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 69 |
| Omeprazole | Omeprazole | 191 | 64 |
| Simvastatin | Simvastatin | 183 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 169 | 58 |
| Glimepiride | Glimepiride | 165 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 45 |
| Gabapentin | Gabapentin | 114 | 38 |
| Meloxicam | Meloxicam | 111 | 57 |
| Januvia | Sitagliptin Phosphate | 110 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 41 |
| Famotidine | Famotidine | 106 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 105 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 35 |
| Folic Acid | Folic Acid | 99 | 28 |
| Alendronate Sodium | Alendronate Sodium | 97 | 27 |
| Ramipril | Ramipril | 95 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 93 | 37 |
| Furosemide | Furosemide | 92 | 39 |
| Lisinopril | Lisinopril | 78 | 25 |
| Farxiga | Dapagliflozin Propanediol | 76 | 22 |
| Trulicity | Dulaglutide | 76 | 19 |
| Azithromycin | Azithromycin | 75 | 67 |
| Fenofibrate | Fenofibrate | 73 | 23 |
| Naproxen | Naproxen | 71 | 39 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 23 |
| Glipizide | Glipizide | 61 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 61 | 17 |
| Montelukast Sodium | Montelukast Sodium | 61 | 19 |
| Eliquis | Apixaban | 57 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 15 |
| Jardiance | Empagliflozin | 53 | 21 |
| Allopurinol | Allopurinol | 49 | 17 |
| Atenolol | Atenolol | 48 | 17 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 48 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 16 |
| Entresto | Sacubitril/Valsartan | 44 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 25 |
| Carvedilol | Carvedilol | 40 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 19 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 39 | 22 |
| Enalapril Maleate | Enalapril Maleate | 38 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 12 |
| Donepezil Hcl | Donepezil Hcl | 37 | 15 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Finasteride | Finasteride | 35 | 12 |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Clotrimazole | Clotrimazole | 32 | 16 |
| Ozempic | Semaglutide | 32 | 11 |
| Ammonium Lactate | Ammonium Lactate | 31 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 31 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 30 | 11 |
| Glipizide Er | Glipizide | 30 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 30 | suppressed |
| Novolin R | Insulin Regular, Human | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 15 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 19 |
| Colchicine | Colchicine | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 15 |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Cefdinir | Cefdinir | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | 11 |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $351.61 · 16 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | AREXVY, JARDIANCE, Kerendia, Korlym, Ozempic, Rybelsus, TRELEGY ELLIPTA, XIFAXAN, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error